Viatris To Shed OTC, APIs And Women’s Health As Biocon Deal Nears Completion

Expecting Further $5bn-$6bn In Pre-Tax Proceeds, As Two Acquisitions Announced

 
• By Dean Rudge
  
Feodora Chiosea/Alamy Stock Vector
Viatris is aiming to generate up to $9bn in pre-tax proceeds • Source: Shutterstock (Feodora Chiosea / Alamy Stock Ve/Alamy Stock Vector)
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business